FDA clears Atara’s IND application in LN for allogeneic CAR T therapy ATA3219

Atara Biotherapeutics announced the U.S. Food and Drug Administration, FDA, has cleared an Investigational New Drug, IND ,application for ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor CAR T-cell monotherapy for the treatment of systemic lupus erythematosus SLE with kidney involvement lupus nephritis or LN . “Expanding upon an extensive clinical experience encompassing the treatment of over 600 patients using our allogeneic T-cell platform in both oncology and autoimmune diseases, we are excited to clinically evaluate the potential of our differentiated allogeneic CAR T-cell approach. We are eager to address the significant unmet need in lupus nephritis as we initiate our Phase 1 trial,” said Pascal Touchon, President and Chief Executive Officer of Atara. “We look forward to bringing the promise and accessibility of a potentially curative off-the-shelf cell therapy option to patients with severe autoimmune diseases, potentially eliminating the burdens of autologous CAR T therapies like costly infrastructure and treatment delays.”